Literature DB >> 18614439

Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat.

M Bebenek1, D Duś, J Koźlak.   

Abstract

PURPOSE: Various studies have revealed that both Fas and its ligand play an important role in cancer biology. The aim of our study was to determine if there is a relationship between the expression of Fas or Fas-ligand in breast cancer and the presence of malignant cells in perilymphatic fat. MATERIAL/
METHODS: Tumor samples from 147 consecutive breast cancer patients, aged 35-81 (median, 59), were subjected to analysis. The expressions of Fas and Fas-ligand were determined immunohistochemically.
RESULTS: The expression of Fas, but not Fas-ligand, was significantly less frequent in breast cancer patients in whom malignant cells infiltrated through the perilymphatic fat (p=0.042). The infiltration of paranodal fatty tissue occurred more often in cases of ductal carcinomas (p=0.008), larger primary tumors (pT>or=2, p=0.030) and regional lymph node involvement (pN>or=1, p=0.021). Univariate analysis revealed that perilymphatic fat infiltration shortened overall survivals in breast cancer patients (p=0.05), similarly to postmenopausal status (p=0.034), age >60 years (p=0.05) and regional lymph node involvement (p=0.05). None of the aforementioned factors, however, was revealed as an independent predictor of survival in multivariate analysis.
CONCLUSIONS: The study showed that lack of Fas in primary breast cancer is associated with perilymphatic fat infiltration. Consequently, both the absence of Fas in the primary tumor and the occurrence of neoplatic cells in paranodal fatty tissue should be considered in the prognosis, complementing existing conventional factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18614439     DOI: 10.2478/v10039-008-0015-y

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  6 in total

1.  Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma.

Authors:  Samaneh Boroumand-Noughabi; Hamid Reza Sima; Kamran Ghaffarzadehgan; Mostafa Jafarzadeh; Hamid Reza Raziee; Hanieh Hosseinnezhad; Omeed Moaven; Mohammad Taghi Rajabi-Mashhadi; Amir Abbas Azarian; Mojtaba Mashhadinejad; Jalil Tavakkol-Afshari
Journal:  BMC Cancer       Date:  2010-06-10       Impact factor: 4.430

2.  Correlation of levels of IL-6 with tumor burden and receptor status in patients of locally advanced carcinoma breast.

Authors:  Binita Goswami; Pankaj Mittal; Nikhil Gupta
Journal:  Indian J Clin Biochem       Date:  2012-06-20

3.  The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea.

Authors:  M A Aller; I Prieto; S Argudo; F de Vicente; L Santamaría; M P de Miguel; J L Arias; J Arias
Journal:  Int J Inflam       Date:  2010-10-05

4.  Expression of cluster of differentiation-95 and relevant signaling molecules in liver cancer.

Authors:  Xuming Wang; Kanglai Wei; Qiongguang Zhang; Sien Zeng; Jing Lin; Li Qiao; Lijiang Liu
Journal:  Mol Med Rep       Date:  2014-12-22       Impact factor: 2.952

5.  Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.

Authors:  Mohammad Hashemi; Aliakbar Fazaeli; Saeid Ghavami; Ebrahim Eskandari-Nasab; Farshid Arbabi; Mohammad Ali Mashhadi; Mohsen Taheri; Wiem Chaabane; Mayur V Jain; Marek J Łos
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

6.  The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma.

Authors:  Olfat Hammam; Ola Mahmoud; Manal Zahran; Sohair Aly; Karim Hosny; Amira Helmy; Amgad Anas
Journal:  Hepat Mon       Date:  2012-11-03       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.